EXACT Therapeutics AS
OOSL:EXTX0.70
NOK
+0.20
(+40.56%)
ISIN
NO0010852213
Return %
Stock
S&P 500
1Y
-65.00
14.20
3Y
-95.33
81.12
5Y
-96.50
68.34
Capital Structure
NOK
•
in mil. unless spec.Working Capital
NOK
•
in mil. unless spec.Growth Rates
NOK
•
in mil. unless spec.Semi-annual Revenue
NOK
•
in mil. unless spec.Semi-annual Earnings Per Share
NOK
•
in mil. unless spec.Semi-annual Dividends Per Share
NOK
•
in mil. unless spec.Company Description
- CEO
- Per Walday
- Full Time Employees
- 11
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Oslo Norway
- IPO Date
- Jul 14, 2020
- Website
- exact-tx.com
- Similar Companies
- Business
- EXACT Therapeutics AS is a clinical-stage biopharmaceutical and medical technology company headquartered in Oslo, Norway, specializing in ultrasound-mediated precision drug delivery platforms for targeted therapeutic applications across oncology, neurology, and gene therapy. Founded in 2012 as a spin-out from GE Healthcare, the company develops and commercializes advanced therapeutic enhancement technologies designed to increase local uptake and efficacy of pharmaceutical agents while reducing systemic toxicity. The company's proprietary product and technology portfolio comprises the Acoustic Cluster Therapy (ACT) platform; PS101, an injectable formulation consisting of microbubble and microdroplet clusters engineered for ultrasound-induced acoustic vaporization and biomechanical sonoporation; specialized ultrasound software and transducer hardware systems co-developed for targeted acoustic activation in clinical settings; oncology drug delivery pipeline candidates, including Phase 2 clinical programs for locally advanced pancreatic ductal adenocarcinoma evaluated in combination with standard-of-care mFOLFIRINOX chemotherapy under the ENACT clinical study; gastrointestinal cancer programs, including Phase 1 clinical applications (ACTIVATE study) targeting liver metastases originating from colorectal cancer; central nervous system drug delivery formulations designed to achieve localized, transient disruption of the blood-brain barrier for the treatment of glioblastoma and neurodegenerative diseases; and targeted gene therapy and immuno-oncology delivery formulations aimed at enhancing the intracellular delivery of macromolecular payloads, nucleic acids, and monoclonal antibodies. EXACT Therapeutics AS conducts operations primarily across Norway and the United Kingdom through clinical research infrastructure and strategic collaborations with academic institutions and healthcare networks, including The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, and Oslo University Hospital. In recent developments, EXACT Therapeutics AS has advanced significant strategic, clinical, and corporate milestones. The company expanded its long-term strategic co-development partnership with GE HealthCare (GE Medical Holding AB) to support ultrasound platform integration and completed a NOK 145 million financing round anchored by GE HealthCare and institutional investors to fund its interventional oncology trials. Clinically, the company initiated and advanced patient enrollment in its multi-center Phase 2 ENACT trial in pancreatic cancer, securing positive safety reviews from the independent Trial Monitoring Committee in early 2026. Structurally, the company initiated a strategic reorganization to transition its capital structure from public equities to private venture and strategic funding vehicles ahead of late-stage registrational trials, culminating in the planned delisting of its shares from the Euronext Growth Oslo exchange in October 2026.